StockData

Celularity vs uniQure

CELU and QURE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CELU and QURE compare

uniQure is the larger company, worth 78 times as much as Celularity ($1.4B against $18.5M).

uniQure grew revenue faster over the last twelve months (30.2% versus −58.1% for Celularity).

Celularity keeps more of each dollar of sales as profit, with a net margin of −246% compared with −1351% at uniQure.

Celularity scores higher on the StockData Score (7 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCELUQURE
Size and price
Market cap$18.5M$1.4B
Share price$0.571$20.78
Change, 1 year−63.2%−30.5%
Change, 5 years−99.2%−27.9%
Beta (5Y)1.893.14
Employees115221
StockData Score
Total score7 (better)4
Valuation score1 (better)0
Growth score12 (better)
Performance score1 (better)0
Health score4 (better)2
Dividend score00
Valuation
P/S1.0× (better)77.2×
P/B–4.4×
FCF yield–−11.2%
Fair value–$6.42
Margin of safety–−224%
Growth
Revenue growth (TTM)−58.1%30.2% (better)
Revenue growth, 5Y average13.2% (better)−15.6%
Profitability
Gross margin19.2%92.5% (better)
Operating margin−264% (better)−1072%
Net margin−246% (better)−1351%
FCF margin–−865%
Return on equity–−158%
Financial health
Debt / equity–0.15
Interest coverage–−3.4×
Current ratio0.1110.01 (better)
Altman Z-score−16.49−0.51 (better)
Piotroski F-score14 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions6.8%96.0%
Held by insiders–2.1%
Insider net buying, 12 months–−$20.2M
Short interest, % of float–12.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.